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Lack of Effect of Pravastatin on Cerebral Blood Flow or
Parenchymal Volume Loss in Elderly at Risk for
Vascular Disease
V. Hester ten Dam, MD; Frieke M.A Box, MSc; Anton J.M. de Craen, PhD;
Dominique M.J. van den Heuvel, MSc; Edward L.E.M. Bollen, MD, PhD; Heather M. Murray, MSc;
Mark A. van Buchem, MD, PhD; Rudi G.J. Westendorp, MD, PhD;
Gerard Jan Blauw, MD, PhD; on behalf of the PROSPER Study Group*
Background and Purpose—Ageing is associated with a decline in cerebral blood flow. Animal studies have shown that
cholesterol-lowering therapy with statins might preserve cerebral blood flow (CBF). We examined the effect of 40 mg
pravastatin on the decline in CBF and brain volume in a subset of elderly subjects participating in the PROspective Study
of Pravastatin in the Elderly at Risk (PROSPER) trial.
Methods—Randomization was not stratified according to whether or not subjects participated in the MRI substudy. In 391
men (n226) and women (n165) aged 70 to 82 years (meanSD, 753.2), we measured total CBF (in mL/min) at
baseline and after a meanSD follow-up of 331.4 months with a gradient-echo phase-contrast MRI technique. Total
CBF was defined as the summed flows in both internal carotid and vertebral arteries. Parenchymal volume (whole brain)
was segmented with the use of in-house–developed semiautomatic software.
Results—Total CBF significantly declined in the placebo-allocated group, from 52183 to 50492 mL/min (P0.0036)
and in the pravastatin-allocated group from 52094 to 50692 mL/min (P0.018). This decline was not significantly
different between treatment groups (P0.56). There was also a significant reduction in brain volume over time
(P0.001), which was not different between the treatment groups (P0.47). When expressed per unit of parenchymal
volume, the decline in CBF over time was no longer statistically significant.
Conclusions—Elderly people at risk for cerebral vascular disease had a significant decline in CBF with increasing age that
was explained by a concomitant reduction in brain volume. Treatment with 40 mg pravastatin daily had no beneficial
effect on total CBF. (Stroke. 2005;36:1633-1636.)
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Ageing is associated with a decline in cerebral blood flow(CBF).1,2 From cross-sectional studies, the rate of this
decline has been estimated at 4.8 mL/min per year.1
Although the exact etiology of this age-dependent reduction
in CBF is largely unknown, several causes have been pro-
posed. Some studies have shown that total CBF is partly
determined by brain volume.3–5 Other studies have indicated
that atherosclerotic disease, small-vessel disease, and a de-
cline in metabolic need might also play a role in the decline
in CBF with age.2,6,7
In animals, cholesterol-lowering therapy with 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors (statins)
has been shown to augment absolute CBF by enhancing
endothelial nitric oxide synthase.8 An improvement of 30% in
CBF induced by statins has been reported in mice.9 A study
in humans with small-vessel disease showed that treatment
with pravastatin improved cerebral vasomotor reactivity but
not CBF.10
We investigated the effect of treatment with 40 mg
pravastatin daily for 3 years compared with placebo on the
decline in total CBF in elderly subjects at risk for vascular
disease. Using MRI, we measured changes in CBF over time
and analyzed all data of CBF as crude measurements and
corrected for brain volume.
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Methods
Setting and Subjects
The PROspective Study of Pravastatin in the Elderly at Risk
(PROSPER) is a double-blind, randomized, placebo-controlled trial
that examined the effect of cholesterol-lowering therapy with 40 mg
pravastatin on vascular events in 5804 men and women, aged 70 to
82 years, with vascular disease or at risk for vascular disease.11,12 A
total of 554 Dutch participants in the PROSPER study had 2
successive MRI scans of the brain. The first MRI was during the
placebo lead-in period and the second MRI after a meanSD
follow-up of 331.4 months. In 391 participants, total CBF was
measured on these 2 occasions. The Leiden University Medical
Center institutional ethics review board approved the protocol for the
MRI study, and all participants gave written, informed consent.
CBF and Parenchymal Volume
We performed MRI of the brain on a system operating at 1.5 T field
strength (Philips Medical Systems). CBF was measured in both
internal carotid arteries and both vertebral arteries by using a
gradient-echo, phase-contrast MRI. We used a triggered gradient-
echo, phase-contrast technique with 1 signal average and retrospec-
tive gating with a peripheral pulse unit. Repetition time (TR)/echo
time (TE) was 14.7/9;1 ms; flip angle, 7.5°; slice thickness, 5 mm,
scan matrix, 256256; and field of view (FOV), 250250 mm. The
scans were performed in a plane perpendicular to the carotid and
vertebral arteries.13 All subjects refrained from smoking at least 90
minutes before CBF was measured. For the parenchyma measure-
ments, we obtained proton density-T2/dual fast-spin-echo images of
all subjects at baseline and follow-up (TE, 27/120 ms; TR, 3000 ms;
echo train length factor, 10; 48 contiguous 3-mm slices; matrix
256256; FOV, 220).
Postprocessing Techniques
The images were analyzed with use of the FLOW software package
(Division of Image Processing, Department of Radiology, Leiden
University Medical Center).14 An automatic method was added to
the package to manually indicate the vessel, after which delineation
of the vessel was drawn automatically.15 With this method, partial-
volume effects were excluded. Volume of flow was calculated by
integrating the flow velocity within this contour multiplied by the
area. Phase differences were calculated according to standard meth-
odology.16 Total CBF was calculated by adding the flow from the
left and right internal carotid arteries to the flow in both vertebral
arteries.13 Parenchyma (whole-brain) volume was segmented with
use of in-house–developed semiautomated software (Division of
Image Processing, Department of Radiology, Leiden University
Medical Center).17 The volume of parenchyma was expressed in
cubic centimeters.
Statistics
Using an  of 5%, we calculated that our study had 80% power to
detect a 20 mL/min (SD, 70 mL/min) difference between the
pravastatin and placebo groups.13 Baseline characteristics for
placebo- and pravastatin-allocated participants are reported as mean
and SD for continuous variates and number (%) for categorical
variates. Baseline CBF depending on various clinical characteristics
was assessed with Student’s t test. The decline in CBF and brain
parenchyma in the placebo- and pravastatin-treated groups was
analyzed with paired t tests. Moreover, a linear mixed model was
performed to study the effect of pravastatin on the progression of
total ischemic lesion load. In some models, CBF was analyzed as a
crude value and later corrected for parenchymal volume.
Results
Baseline characteristics for the 391 participants are shown in
Table 1. No significant differences were found, except for
smoking: 32 subjects (17%) in the pravastatin group were
smokers versus 57 subjects (29%) in the placebo group
(P0.004). Table 2 shows baseline CBF in relation to various
clinical characteristics. Women had significant lower CBF
(meanSD, 50789 mL/min) than men (meanSD,
53087 mL/min; P0.01). There was no significant differ-
ence in CBF for any of the other characteristics, including a
history of vascular disease, stroke, or transient ischemic
attack.
To assess the effect of pravastatin on cholesterol reduction,
we calculated the 3-months reductions in total cholesterol,
LDL cholesterol, and HDL cholesterol in our study groups.
After 3 months of follow-up, mean total cholesterol in the 193
subjects allocated to pravastatin was significantly reduced,
from 5.70.8 to 4.30.7 mmol/L. Total cholesterol remained
unaltered at 5.70.9 mmol/L in the 198 placebo-treated
subjects. In the pravastatin-treated subjects, LDL cholesterol
was reduced, from 3.90.8 to 2.50.6 mmol/L, and HDL
cholesterol increased from 1.20.3 to 1.30.4 mmol/L. LDL
and HDL cholesterol remained unaltered in the placebo-
treated subjects. The total cholesterol, LDL, and HDL
changes in the 193 pravastatin-treated patients were similar to
the changes reported in the total group of subjects in the
PROSPER study.12
The decline in CBF during the study period was 14.0
mL/min (95% confidence interval, 2.4 to 25.5, P0.018) in
the pravastatin group and 17.7 mL/min (95% confidence
interval, 5.8 to 29.5, P0.0036) in the placebo group (Table
3). This translates to a decline of 5.1 mL/min per year in the
pravastatin group and a decline of 6.4 mL/min per year in the
placebo group. The reduction in CBF was not significantly
different between the 2 treatment groups (P0.56). In both
treatment groups, a similar significant reduction in brain
volume over time was also observed (P0.001 within both
treatment groups, P0.47 between groups; Table 3). When
CBF was expressed per unit parenchymal volume, the decline
in CBF over time was no longer significant (Table 3). Results
from the linear mixed models also indicated no significant
differences between treatment groups, P0.66 for crude CBF
and P0.56 for CBF corrected for parenchymal volume.
TABLE 1. Baseline Characteristics
Characteristic
Placebo
(n198)
Pravastatin
(n193) P
Age, y 75.1 (3.3) 75.0 (3.1) 0.91
Men 120 (60.6) 106 (54.9) 0.26
Systolic blood pressure, mm Hg 156.5 (20.4) 157.8 (22.2) 0.55
Diastolic blood pressure, mm Hg 86.6 (10.8) 85.0 (11.2) 0.17
Total cholesterol, mmol/L 5.7 (0.9) 5.7 (0.8) 0.73
LDL cholesterol, mmol/L 3.9 (0.8) 3.9 (0.8) 0.43
HDL cholesterol, mmol/L 1.3 (0.3) 1.2 (0.3) 0.40
Current smoker 57 (28.8) 32 (16.6) 0.004
History of diabetes 36 (18.2) 28 (14.5) 0.33
History of hypertension 116 (58.6) 128 (66.3) 0.11
History of myocardial infarction 26 (13.1) 22 (11.4) 0.60
History of stroke or transient
ischemic attack
40 (20.2) 26 (13.5) 0.08
History of any vascular disease 89 (45.0) 83 (43.0) 0.70
Continuous variates are mean and (SD); categorical variates as n and (%).
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Discussion
In this elderly population at risk for vascular disease, we
found a significant decline in total CBF over an average
period of 33 months. This reduction was not influenced by 40
mg pravastatin daily and disappeared when we corrected for
the concomitant decrease in brain parenchymal volume.
A previous cross-sectional study estimated the age-dependent
decline in CBF in a small group of 88-year-old subjects at 4.8
mL/min per year.1 In this age group of 70 to 82 years, we found a
decline of 5.8 mL/min per year. However, when total CBF was
expressed per unit brain parenchymal volume, CBF did not decline
with increasing age. This indicates that in the elderly, perfusion of
brain tissue is kept constant, most likely by the same vascular
autoregulatory mechanisms operative at younger ages.18,19 Al-
though the causal relation between brain tissue and total CBF in the
elderly is yet unclear, the present finding indicates that the reduction
in total CBF with increasing age may be caused by a reduction in
brain volume and not primarily by a reduction in brain perfusion.
In contrast to animal studies, in our study we found no effect of
pravastatin on total CBF. We have shown previously that our
method is sensitive to detect CBF changes, based on widespread
small-vessel disease.20 Therefore, we also expected to demonstrate
total CBF changes due to atherosclerosis of the large vessels.
However, our results provide evidence that statins do not preserve
brain perfusion and are consistent with earlier reports of PROSPER
that treatment with 40 mg pravastatin daily does not reduce the risk
of cerebral vascular disease in an elderly population.12
We found a significant difference in CBF between men and
women. We think that this difference does not affect the interpre-
tation of our results because (1) the decline in CBF over time was
analyzed with paired t tests, which takes into account intraindividual
differences, and (2) the distribution of men and women was similar
TABLE 2. Baseline CBF Dependent on Various Clinical Characteristics
No. Mean (SD)
Mean Difference
(95% CI) P
Age, y
74.6
74.6
195
196
527.8 (94.6)
513.6 (81.0)
14.3 (3.2, 31.8) 0.11
Sex
Men
Women
226
165
530.4 (86.7)
507.3 (88.7)
23.1 (5.5, 40.7) 0.01
Systolic blood pressure, mm Hg
158
158
203
188
522.9 (92.7)
518.3 (83.3)
4.6 (13.0, 22.2) 0.61
Diastolic blood pressure, mm Hg
85
85
200
191
524.4 (91.0)
516.8 (85.3)
7.6 (10.0, 25.1) 0.40
Total cholesterol, mmol/L
5.7
5.7
195
196
519.9 (88.2)
521.4 (88.4)
1.5 (19.1, 16.0) 0.87
LDL cholesterol, mmol/L
3.8
3.8
198
193
518.6 (89.9)
522.8 (86.6)
4.2 (21.8, 13.3) 0.64
HDL cholesterol, mmol/L
1.2
1.2
197
194
516.2 (83.4)
525.3 (92.8)
9.1 (26.7, 8.4) 0.31
Current smoker
Yes
No
89
302
533.3 (91.4)
517.0 (87.0)
16.3 (4.5, 37.2) 0.12
History of diabetes
Yes
No
64
327
517.9 (89.0)
521.2 (88.2)
3.4 (27.1, 20.4) 0.78
History of hypertension
Yes
No
244
147
519.1 (86.0)
523.3 (92.0)
4.2 (22.3, 14.0) 0.65
History of myocardial infarction
Yes
No
48
343
506.5 (89.6)
522.7 (87.9)
16.2 (42.9, 10.5) 0.23
History of stroke or transient ischemic attack
Yes
No
66
325
518.3 (72.8)
521.2 (91.1)
2.9 (26.3, 20.5) 0.81
History of any vascular disease
Yes
No
172
219
517.2 (84.2)
523.4 (91.3)
6.3 (24.0–11.4) 0.49
CI indicates confidence interval.
Continuous variates were dichotomized at the median.
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in the placebo and pravastatin groups. Moreover, current smoking
was more prevalent in the placebo group. This could have caused a
greater decline in CBF over time compared with the group treated
with pravastatin. This means that any possible benefit of pravastatin
on CBF would have been more pronounced. Therefore, we think
that the unequal distribution of smoking between the 2 treatment
groups did not influence our results.
In conclusion, in this study we found a significant decline in
CBF with increasing age that was explained by a concomitant
reduction in brain volume. Both the uncorrected change of CBF
over time and the change in CBF corrected for parenchymal
volume were not influenced by 40 mg pravastatin daily.
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